Patricia Inacio, PhD, science writer —

Alzamend Neuro is seeking regulatory approval to launch the first U.S. trial of ALZN002, its investigational vaccine for mild to moderate dementia related to Alzheimer’s disease. If the U.S. Food and Drug Administration (FDA) approves the company’s investigational new drug application (IND), Alzamend will start a Phase 1/2a…

The U.S. Food and Drug Administration (FDA) has greenlit Annovis Bio to conduct a Phase 2/3 trial to test its investigational treatment buntanetap in people with moderate Alzheimer’s disease. The study, expected to start later this year, follows the positive findings from a Phase 2a trial…

Alpha Cognition’s candidate oral tablet ALPHA-1062, for mild to moderate Alzheimer’s disease, showed efficacy as a bioequivalent substitute for the approved therapy Razadyne (galantamine), according to top-line data from a trial with healthy volunteers. Per this new data, as a delayed-release tablet, ALPHA-1062 showed…

The U.S. Food and Drug Administration (FDA) has kept to its initial decision to reject a request by Acadia Pharmaceuticals to expand Nuplazid (pimavanserin) to treat hallucinations and delusions associated with Alzheimer’s disease-related psychosis. In a complete response letter (CRL) indicating it had finished its review of the…

A large clinical trial has received $45 million in U.S. funding to evaluate the efficacy of benfotiamine — a lab-made precursor of thiamine or vitamin B1 — in slowing the cognitive decline of those with mild Alzheimer’s disease or mild cognitive impairment. The five-year grant was awarded by the…

ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for the approved therapy Razadyne, according to a pivotal trial with healthy volunteers. The pro-drug therapy — meaning that the medication is metabolized in the body, after administration — showed positive…

Early treatment with crenezumab, an investigational anti-amyloid antibody, failed to significantly slow or prevent cognitive decline in a group of people with a genetic risk for early-onset Alzheimer’s disease, data from a Phase 2 trial show. Numerical differences favoring crenezumab over a placebo were seen across…

A Phase 2 clinical trial will test BMND08, an investigational oral therapy based on a natural psychedelic, in treating depression and anxiety in people with Alzheimer’s disease, its developer, Biomind Labs, reported. The company’s announcement follows the trial’s approval by an institutional review board in Argentina.

Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial of AL001, an investigational oral therapy for dementia related to Alzheimer’s disease. This multiple ascending dose (MAD) part follows positive results from a Phase 1 trial. Topline data…

Eisai has completed a rolling submission to the U.S. Food and Drug Administration (FDA) to seek approval for lecanemab (BAN2401), an investigational antibody for the treatment of early Alzheimer’s disease accompanied by beta-amyloid deposits in the brain. The request — made in the form of a biologics…